Functional recovery in parkinsonian monkeys treated with GDNF

Primate models of movement disorders of basal ganglia origin

DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824

GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons

Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079

New stereological methods for counting neurons

West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940

Biochemical pathophysiology of Parkinson's disease.

Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 850

Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain

Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654

A consideration of neural counting methods

Coggeshall, R. E. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90339-a · Cited by 540

Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

Hoffer, B. J., Hoffman, A. F., Bowenkamp, K., Huettl, P. F., Hudson, J., Martin, D., Lin, L.-F. H., & Gerhardt, G. A. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90218-6 · Cited by 453

GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo

Kearns, C. M., & Gash, D. M. (1995) · Brain Research · doi:10.1016/0006-8993(94)01366-p · Cited by 379

Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308

Glial cell line-derived neurotrophic factor family ligands and their therapeutic potential

Sidorova, Y. A., & Saarma, M. (2016) · Molecular Biology · doi:10.1134/s0026893316040105 · Cited by 21

Pharmacological MRI (phMRI) Monitoring of Treatment in Hemiparkinsonian Rhesus Monkeys

Luan, L., Ding, F., Ai, Y., Andersen, A. H., Hardy, P., Forman, E., Gerhardt, G. A., Gash, D. M., Grondin, R., & Zhang, Z. (2008) · Cell Transplantation · doi:10.3727/096368908784423319 · Cited by 21

HSV vector-delivery of GDNF in a rat model of PD: partial efficacy obscured by vector toxicity

Monville, C., Torres, E., Thomas, E., Scarpini, C. G., Muhith, J., Lewis, J., Finn, J., Smith, C., Cai, S., Efstathiou, S., et al. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.082 · Cited by 21

Glial cell line neurotrophic factor-family receptor α-1 is present in central neurons with distinct phenotypes

Sarabi, A., Hoffer, B. J., Olson, L., & Morales, M. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00559-6 · Cited by 21

Gene therapy for neurological disease

Tuszynski, M. H. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.5.815 · Cited by 21

Development of an HSV-Based Vector for the Treatment of Parkinson's Disease

Fink, D. J., Poliani, P. L., Oligino, T., Krisky, D. M., Goins, W. F., & Glorioso, J. C. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6395 · Cited by 21

Understanding the Potential of Genome Editing in Parkinson’s Disease

Arango, D., Bittar, A., Esmeral, N. P., Ocasión, C., Muñoz-Camargo, C., Cruz, J. C., Reyes, L. H., & Bloch, N. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179241 · Cited by 24

Morphological evidence for dopamine interactions with pallidal neurons in primates

Eid, L., & Parent, M. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00111 · Cited by 20

Neurotrophic factors for the treatment of Parkinson's disease

Chiocco, M. J., Harvey, B. K., Wang, Y., & Hoffer, B. J. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70024-5 · Cited by 20

Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence

Kelps, K. A., Turchan-Cholewo, J. T., Hascup, E. R., Taylor, T. L., Gash, D. M., Gerhardt, G. A., & Bradley, L. H. (2011) · Neuropeptides · doi:10.1016/j.npep.2011.03.003 · Cited by 20

Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts

Clavreul, A., Sindji, L., Aubert‐Pouëssel, A., Benoît, J., Meneï, P., & Montero‐Menei, C. N. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.11.006 · Cited by 20

Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity

Emerich, D. F., Kordower, J. H., Chu, Y., Thanos, C. G., Bintz, B. E., Paolone, G., & Wahlberg, L. U. (2019) · Neural Plasticity · doi:10.1155/2019/6286197 · Cited by 20

Long-term, stable, targeted biodelivery and efficacy of GDNF from encapsulated cells in the rat and Goettingen miniature pig brain

Wahlberg, L. U., Emerich, D. F., Kordower, J. H., Bell, W., Fradet, T., & Paolone, G. (2020) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2020.04.001 · Cited by 20

Gene Therapy in the Management of Parkinson’s Disease: Potential of GDNF as a Promising Therapeutic Strategy

Behl, T., Kaur, I., Kumar, A., Mehta, V., Zengin, G., & Arora, S. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200817164051 · Cited by 22

Mechanistic Insight from Preclinical Models of Parkinson’s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy

Delgado-Minjares, K. M., Martínez‐Fong, D., Martínez-Dávila, I. A., Bañuelos, C., Gutiérrez-Castillo, M. E., Blanco-Álvarez, V. M., Cárdenas‐Aguayo, M. D. C., Luna‐Muñoz, J., Pacheco‐Herrero, M., & Soto-Rojas, L. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111702 · Cited by 20

Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

Garbayo, E., Ansorena, E., Lanciego, J. L., Aymerich, M., & Blanco‐Prieto, M. J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.003 · Cited by 20

Electrophysiological localization of the substantia nigra in the parkinsonian nonhuman primate

Starr, P. A., Subramanian, T., Bakay, R. A. E., & Wichmann, T. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.93.4.0704 · Cited by 20

Intrastriatal grafting of glomus cells ameliorates behavioral defects of Parkinsonian rats

HAO, G., Yao, Y., WANG, J., ZHANG, L., Viroonchatapan, N., & WANG, Z. (2002) · Physiology & Behavior · doi:10.1016/s0031-9384(02)00938-1 · Cited by 20

Chapter 11 Neurotrophic Factors and the Aging Brain

Mattson, M. P., & Lindvall, O. (1997) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(08)60061-9 · Cited by 20

Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment

Inoue, T., Tsui, J. K. C., Wong, N. L. M., Wong, S. Y., Suzuki, F., & Kwok, Y. N. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01254-8 · Cited by 20

Designing neuroprotection trials in Parkinson's disease

Kieburtz, K. D. (2003) · Annals of Neurology · doi:10.1002/ana.10484 · Cited by 20

Cytokine-, Neurotrophin-, and Motor Rehabilitation-Induced Plasticity in Parkinson’s Disease

Policastro, G., Brunelli, M., Tinazzi, M., Chiamulera, C., Emerich, D. F., & Paolone, G. (2020) · Neural Plasticity · doi:10.1155/2020/8814028 · Cited by 21

Direct conversion of mouse fibroblasts to GABAergic neurons with combined medium without the introduction of transcription factors or miRNAs

Xu, H., Wang, Y., He, Z., Yang, H., & Gao, W. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1060382 · Cited by 19

GFR α‐1 receptor expression in the aging nigrostriatal and mesoaccumbens pathways

Pruett, B. S., & Salvatore, M. F. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06963.x · Cited by 19

The Cortical and Striatal Gene Expression Profile of 100 Hz Electroacupuncture Treatment in 6-Hydroxydopamine-Induced Parkinson's Disease Model

Huo, L., Liang, X., Li, B., Liang, J., He, Y., Jia, Y., Jia, J., Gong, X., Yu, F., & Wang, X. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/908439 · Cited by 19

MicroRNA machinery in Parkinson’s disease: a platform for neurodegenerative diseases

Saghazadeh, A., & Rezaei, N. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1114886 · Cited by 19

Neuroprotective Surgical Strategies in Parkinson’s Disease: Role of Preclinical Data

Torres-Martinez, N., Molet, J., Moro, C., Mitrofanis, J., & Benabid, A. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102190 · Cited by 19

Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity

Luz, M., Allen, P. C., Bringas, J., Boiko, C., Stockinger, D. E., Nikula, K. J., Lewis, O. T., Woolley, M., Fibiger, H. C., Bankiewicz, K. S., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2222-z · Cited by 19

Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons

Schmidt, F., Douaron, G. L., Champy, P., Amar, M., Séon‐Méniel, B., Raisman‐Vozari, R., & Figadère, B. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.067 · Cited by 19

Sorting Protein-related Receptor SorLA Controls Regulated Secretion of Glial Cell Line-derived Neurotrophic Factor

Geng, Z., Xu, F.-Y., Huang, S., & Chen, Z.-Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.246413 · Cited by 19

Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson’s disease

Anastasía, A., de Erausquin, G. A., Wojnacki, J., & Mascó, D. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04856.x · Cited by 19

Towards New Therapies for Parkinson's Disease

Finkelstein, D. I. (2011) · InTech eBooks · doi:10.5772/954 · Cited by 19

Mutation Analysis of the Glial Cell Line-Derived Neurotrophic Factor Gene in Parkinson's Disease

Wartiovaara, K., Hytönen, M. K., Vuori, M., Paulin, L., Rinne, J. O., & Sariola, H. V. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6857 · Cited by 19

Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats

Palmer, M. R., Granholm, A.-C., van Horne, C. G., Giardina, K., Freund, R. K., Moorhead, J. W., & Gerhardt, G. A. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03084-5 · Cited by 19

Effects of intra-striatal GDNF on motor coordination and striatal electrophysiology in aged F344 rats☆

Bowenkamp, K. E., Ujhelyi, L., Cline, E. J., & Bickford, P. C. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00112-8 · Cited by 19

Improved therapies for Parkinson's disease: life beyond dopamine D2D3 receptors agonists

Williams, M. J., Wright, S., & Lloyd, G. K. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)90650-7 · Cited by 19

Engineering of electrospun nanofiber scaffolds for repairing brain injury

Du, W., Wang, T., Shu-yun, H., Luan, J., Tian, F., Ma, G., & Xue, J. (2023) · Engineered Regeneration · doi:10.1016/j.engreg.2023.04.001 · Cited by 18

Intracerebral injections of DNA nanoparticles encoding for a therapeutic gene provide partial neuroprotection in an animal model of neurodegeneration

Yurek, D. M., Hasselrot, U., Sesenoglu‐Laird, O., Padegimas, L., & Cooper, M. J. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.06.010 · Cited by 18

Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers

Mitra, S., Turconi, G., Darreh‐Shori, T., Mätlik, K., Aquilino, M., Eriksdotter, M., & Andressoo, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.714186 · Cited by 18

Rola czynników neurotroficznych w procesach regeneracji układu nerwowego

Machaliński, B., Łażewski-Banaszak, P., Dąbkowska, E., Paczkowska, E., Gołąb-Janowska, M., & Nowacki, P. (2012) · Neurologia i Neurochirurgia Polska · doi:10.5114/ninp.2012.32354 · Cited by 18

GDNF isoform affects intracellular trafficking and secretion of GDNF in neuronal cells

Wang, Y., Geng, Z., Zhao, L., Huang, S., Sheng, A.-L., & Chen, Z.-Y. (2008) · Brain Research · doi:10.1016/j.brainres.2008.05.087 · Cited by 18

Glial cell line-derived neurotrophic factor protects midbrain dopamine neurons from the lethal action of the weaver gene: a quantitative immunocytochemical study

Broome, J. D., Wills, K. V., Lapchak, P. A., Ghetti, B. F., Camp, L. L., & Bayer, S. A. (1999) · Developmental Brain Research · doi:10.1016/s0165-3806(99)00065-6 · Cited by 18

Increase in secretion of glial cell line-derived neurotrophic factor from glial cell lines by inhibitors of vacuolar ATPase

Nishiguchi, M., Tokugawa, K., Yamamoto, K., Akama, T., Nozawa, Y., Chaki, S., Ueki, T., Kameo, K., & Okuyama, S. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(02)00139-0 · Cited by 18

Gene therapy for Parkinson's disease

Lawlor, P. A., & During, M. J. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940400746x · Cited by 18

Chapter 9 Encapsulated neural transplants

Tseng, J., & Aebischer, P. (2000) · Progress in brain research · doi:10.1016/s0079-6123(00)27010-6 · Cited by 18

Enhanced delivery of [125I]glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification

Jiao, S., Miller, P. J., & Lapchak, P. A. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13265-1 · Cited by 18

Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF

Smith, R. C., O’Bryan, L. M., Mitchell, P. J., Leung, D., Ghanem, M., Wilson, J. M., Hanson, J. C., Sossick, S., Cooper, J., Huang, L., et al. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.03.002 · Cited by 17

Neurotoxins as Preclinical Models for Parkinson’s Disease

Segura‐Aguilar, J. (2018) · Neurotoxicity Research · doi:10.1007/s12640-017-9856-0 · Cited by 17

High Concentration of Glial Cell Line-Derived Neurotrophic Factor Protects Primary Astrocytes from Apoptosis

Wang, Y., Qin, Y., Guo, T.-W., Tang, C., Liu, L., & Gao, D. (2018) · Developmental Neuroscience · doi:10.1159/000487853 · Cited by 18

Targeting delivery in Parkinson's disease

Newland, B., Dunnett, S. B., & Dowd, E. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.003 · Cited by 17

Mechanisms of Neuronal Apoptosis and Excitotoxicity

Mattson, M. P. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-106-0_1 · Cited by 17

Restorative Effects of GDNF on Striatal Dopamine Release in Rats Treated with Neurotoxic Doses of Methamphetamine

Cass, W. A., Manning, M. W., & Bailey, S. L. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05190.x · Cited by 17

The therapeutic potentials of neurotrophic factors for diseases of the nervous system

Gao, W., Weil, R. J., Dugich‐Djordjevic, M. M., & Lu, B. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.4.325 · Cited by 17

Neural transplantation in animal models of multiple system atrophy: a review

Wenning, G. K., Granata, R., Puschban, Z., Scherfler, C., & Poewe, W. H. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6369-6_10 · Cited by 17

Neurotoxic Mechanism and Shortcomings of MPTP, 6-OHDA, Rotenone and Paraquat-induced Parkinson’s Disease Animal Models

Okyere, S. K., Zeng, C., Dong, Y., & Hu, Y. (2020) · Venoms and Toxins · doi:10.2174/2666121701999201104163407 · Cited by 18

Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency

Fan, X. T., Zhao, F., Ai, Y., Andersen, A. H., Hardy, P., Ling, F., Gerhardt, G. A., Zhang, Z., & Quintero, J. E. (2014) · Brain Research · doi:10.1016/j.brainres.2013.12.035 · Cited by 16

Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease

Ge, G., Chen, C., Guderyon, M. J., Liu, J., He, Z., Yu, Y., Clark, R. A., & Li, S. (2018) · Stem Cells and Development · doi:10.1089/scd.2018.0030 · Cited by 16

Study on Effect of Striatal mGluR2/3 in Alleviating Motor Dysfunction in Rat PD Model Treated by Exercise Therapy

Chen, P., & Li, X. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00255 · Cited by 16

Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates

Fontán, A., Rojo, A., Sánchez‐Pernaute, R., Hernández, I., López, I., Castilla, C., Albísua, J., Higueras, A. P., Al-Rashid, I., Rábano, A., et al. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00005-6 · Cited by 16

Alterations in the expressions of mRNA for GDNF and its receptors in the ventral midbrain of rats exposed to subchronic phencyclidine

Semba, J., Akanuma, N., Wakuta, M., Tanaka, N., & Suhara, T. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.02.011 · Cited by 16

Neuroprotective Strategies Based on Targeting of Postreceptor Signaling Events

Mattson, M. P. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-475-7_16 · Cited by 16

Gene Therapies for Parkinson’s Disease

Bohn, M. C., & Choi-Lundberg, D. L. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-478-8_17 · Cited by 16

Modulation of Nigrostriatal Dopaminergic Transmission by Antisense Oligodeoxynucleotide Against Brain-Derived Neurotrophic Factor

Lau, Y., Hao, R., Fung, Y. K., Fu, L.-S., Bishop, J. F., Pfeiffer, R. F., & Mouradian, M. M. (1998) · Neurochemical Research · doi:10.1023/a:1022482518292 · Cited by 16

Apoptosis induction by a dopaminergic neurotoxin, 1-methyl-4-phenylpyridinium ion (MPP+), and inhibition by epidermal growth factor in GH3 cells

Yoshinaga, N., Murayama, T., & Nomura, Y. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00304-x · Cited by 16

Pathophysiology of movement disorders studied using PET

Leenders, K. L. (1997) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6842-4_5 · Cited by 16

Partial Reconstruction of the Nigrostriatal Circuit along a Preformed Molecular Guidance Pathway

Ghosh, B., Zhang, C., Ziemba, K. S., Fletcher, A. M., Yurek, D. M., & Smith, G. M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.008 · Cited by 15

Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling

Kasanga, E. A., Han, Y., Navarrete, W., McManus, R., Shifflet, M. K., Parry, C., Barahona, A., Manfredsson, F. P., Nejtek, V. A., Richardson, J. R., et al. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114435 · Cited by 15

Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs

Kasanga, E. A., Han, Y., Shifflet, M. K., Navarrete, W., McManus, R., Parry, C., Barahona, A., Nejtek, V. A., Manfredsson, F. P., Kordower, J. H., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114509 · Cited by 15

Convection enhanced delivery of different molecular weight tracers of gadolinium-tagged polylysine

Hardy, P., Keeley, D., Schorn, G., Forman, E., Ai, Y., Venugopalan, R., Zhang, Z., & Bradley, L. H. (2013) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2013.07.013 · Cited by 15

Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies

Zaghmi, A., Drouin‐Ouellet, J., Brambilla, D., & Gauthier, M. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120461 · Cited by 17

Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exasperates parkinsonian symptoms

Chao, O. Y.-H., Huston, J. P., von Bothmer, A., & Pum, M. E. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.043 · Cited by 15

A Model of GDNF Gene Therapy in Mice with 6-Hydroxydopamine Lesions: Time Course of Neurorestorative Effects and ERK1/2 Activation

Lindgren, N., Francardo, V., Quintino, L., Lundberg, C., & Cenci, M. A. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-012146 · Cited by 15

Regenerative Therapies for Parkinson’s Disease: An Update

Stoker, T. B., & Barker, R. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0294-1 · Cited by 15

Neurotrophic Factors and Their Receptors

(1995) · Nature Biotechnology · doi:10.1038/nbt1195-1170 · Cited by 15

Dynamic changes in dopamine neuron function after DNSP-11 treatment: Effects in vivo and increased ERK 1/2 phosphorylation in vitro

Fuqua, J. L., Littrell, O. M., Lundblad, M., Turchan-Cholewo, J. T., Abdelmoti, L. G., Galperin, E., Bradley, L. H., Cass, W. A., Gash, D. M., & Gerhardt, G. A. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.007 · Cited by 15

Effects of fibroblast growth factors on MPTP-induced parkinsonian syndrome in mice

Kryzhanovsky, G. N., Kucheryanu, V. G., Pozdnyakov, O. M., Kladkevich, E. B., Krupina, N. A., Никушкин, Е. В., & Oomura, Y. (1997) · Pathophysiology · doi:10.1016/s0928-4680(96)00160-5 · Cited by 15

Toward trophic treatment in parkinsonism: A primate step

Olson, L. (1996) · Nature Medicine · doi:10.1038/nm0496-400 · Cited by 15

Synthesis of jiadifenin using Mizoroki–Heck and Tsuji–Trost reactions

Harada, K., Imai, A., Uto, K., Carter, R. G., Kubo, M., Hioki, H., & Fukuyama, Y. (2015) · Tetrahedron · doi:10.1016/j.tet.2015.02.090 · Cited by 15

Parkinson's Disease Management: Towards a New Paradigm

Guttman, M., & Suchowersky, O. (1999) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000010x · Cited by 15

Signal transduction and neurosurvival in experimental models of brain injury

Butler, T. L., Kassed, C. A., & Pennypacker, K. R. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(02)00926-7 · Cited by 15

Therapeutic gene transfer with herpes-based vectors: studies in Parkinson's disease and motor nerve regeneration

Fink, D. J. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00358-3 · Cited by 15

MPTP-Induced Pallidal Lesions in Rhesus Monkeys

Zhang, Z., Zhang, M., Ai, Y., Avison, C., & Gash, D. M. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6976 · Cited by 15

Chapter 12 The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies

Bingaman, K. D., & Bakay, R. A. E. (2000) · Progress in brain research · doi:10.1016/s0079-6123(00)27013-1 · Cited by 15

Pathogenic role of glial cells in Parkinson's disease

Przedborski, S., & Goldman, J. E. (2003) · Advances in molecular and cell biology · doi:10.1016/s1569-2558(03)31043-4 · Cited by 15

Do Naturally Occurring Antioxidants Protect Against Neurodegeneration of the Dopaminergic System? A Systematic Revision in Animal Models of Parkinson's Disease

Costas‐Ferreira, C., & Faro, L. R. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210421092725 · Cited by 14

Moderate intensity aerobic exercise alleviates motor deficits in 6-OHDA lesioned rats and reduces serum levels of biomarkers of Parkinson's disease severity without recovery of striatal dopamine or tyrosine hydroxylase

Kasanga, E. A., Soto, I., Centner, A., McManus, R., Shifflet, M. K., Navarrete, W., Han, Y., Lisk, J. P., Ehrhardt, T., Wheeler, K., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114875 · Cited by 14

Translational research for Parkinson׳s disease: The value of pre-clinical primate models

Badin, R. A., Vadori, M., Cozzi, E., & Hantraye, P. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.038 · Cited by 14

Induced Cognitive Impairments Reversed by Grafts of Neural Precursors: A Longitudinal Study in a Macaque Model of Parkinson's Disease

Wianny, F., Dzahini, K., Fifel, K., Wilson, C. R. E., Bernat, A., Dolmazon, V., Misery, P., Lamy, C., Giroud, P., Cooper, H. M., et al. (2022) · Advanced Science · doi:10.1002/advs.202103827 · Cited by 14

Modulation of the Tyrosine Kinase Receptor Ret/Glial Cell-Derived Neurotrophic Factor (GDNF) Signaling: A New Player in Reproduction Induced Anterior Pituitary Plasticity?

Guillou, A., Romanò, N., Bonnefont, X., Tissier, P. L., Mollard, P., & Martin, A. (2011) · Endocrinology · doi:10.1210/en.2010-0673 · Cited by 14

Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats

Renko, J., Bäck, S., Voutilainen, M. H., Piepponen, P. T., Reenilä, I., Saarma, M., & Tuominen, R. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0872-8 · Cited by 14

Oral administration of docosahexaenoic acid activates the GDNF-MAPK-CERB pathway in hippocampus of natural aged rat

Jiang, L., Yan, S., Wang, J., & Liang, Q.-Y. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.784341 · Cited by 14

Young and middle-aged rats exhibit isometric forelimb force control deficits in a model of early-stage Parkinson's disease

Bethel-Brown, C. S., Morris, J. K., & Stanford, J. A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.002 · Cited by 14

Gene therapy in Parkinson?s disease

Eberhardt, O., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0947-x · Cited by 14

Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?

Thi, N., Saillour, P., Ferrero, L., Paunio, T., & Mallet, J. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302844 · Cited by 14

Chronic Intracerebral Delivery of Trophic Factors via a Programmable Pump as a Treatment for Parkinsonism

Grondin, R., Zhang, Z., Elsberry, D. D., Gerhardt, G. A., & Gash, D. M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-142-6:257 · Cited by 14

Marked Dopaminergic Cell Loss Subsequent to Developmental, Intranigral Expression of Glial Cell Line-Derived Neurotrophic Factor

Chun, H. S., Yoo, M. S., DeGiorgio, L. A., Volpe, B. T., Peng, D., Baker, H., Peng, C., & Son, J. H. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7842 · Cited by 14

Towards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans

Bezdjian, A., Kraaijenga, V. J. C., Ramekers, D., Versnel, H., Thomeer, H. G. X. M., Klis, S. F. L., & Grolman, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121981 · Cited by 13

Increased Physiological GDNF Levels Have No Effect on Dopamine Neuron Protection and Restoration in a Proteasome Inhibition Mouse Model of Parkinson’s Disease

Olfat, S., Mätlik, K., Kopra, J. J., Garton, D. R., Iivanainen, V., Bhattacharya, D., Jakobsson, J., Piepponen, P. T., & Andressoo, J. (2023) · eNeuro · doi:10.1523/eneuro.0097-22.2023 · Cited by 13

Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques

Stenslik, M. J., Evans, A., Pomerleau, F., Weeks, R. M., Huettl, P. F., Foreman, E., Turchan-Cholewo, J. T., Andersen, A. H., Cass, W. A., Zhang, Z., et al. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.03.006 · Cited by 13

Mechanisms of neuronal cell death

Morrison, R. S., Kinoshita, Y., Xiang, H., Johnson, M. D., Kuntz, C., Ghatan, S., Ho, J. T., & Schwartzkroin, P. A. (1998) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/(sici)1098-2779(1998)4:3 · Cited by 15

Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys

Grondin, R., Zhang, Z., Ai, Y., Cass, W. A., Maswood, N., Andersen, A. H., Elsberry, D. D., Klein, M. C., Gerhardt, G. A., & Gash, D. M. (2002) · Brain · doi:10.1093/brain/awf234 · Cited by 280

Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson’s disease

Grondin, R., & Gash, D. M. (1998) · Journal of Neurology · doi:10.1007/pl00007744 · Cited by 134

Trophic factor distribution predicts functional recovery in parkinsonian monkeys

Gash, D. M., Zhang, Z., Ai, Y., Grondin, R., Coffey, R. J., & Gerhardt, G. A. (2005) · Annals of Neurology · doi:10.1002/ana.20549 · Cited by 97

Neuroprotective and neurorestorative properties of GDNF

Gash, D. M., Zhang, Z., & Gerhardt, G. A. (1998) · Annals of Neurology · doi:10.1002/ana.410440718 · Cited by 159

Histological Effects of Intraputaminal Infusion of Glial Cell Line-Derived Neurotrophic Factor in Parkinson Disease Model Macaque Monkeys

Oiwa, Y., NAKAI, K., & Itakura, T. (2006) · Neurologia medico-chirurgica · doi:10.2176/nmc.46.267 · Cited by 21